Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stock Scan February 2018: Wet But Above Water

Executive Summary

The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.

Advertisement

Related Content

Stock Scan April 2018: Pharma's Fizz Falls Flat
Valeant Claims Progress, Asks Investors For Patience
Celgene Joins Troubled MS Club With Refuse To File For Ozanimod From US FDA
Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy
Appointments: Changes At Hikma, Bluebird Bio, Celgene, Alkermes, Cell Medica, Editas Medicine, Futura Medical, Corline Biomedical And Horizon Discovery
Biogen Spooks With Phase III Aducanumab Changes
Asia Movers To Watch: Astellas, Kyowa Hakko, CMIC, CFDA
Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win
Sanofi Starts 2018 As It Means To Go On: More Transactions Expected
CSL Looks Beyond Organic Growth To External Innovation

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100536

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel